Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480231 | 0.92 | SIGMAR1 (0.54) | FAAHMEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL3047497 | 0.85 | KDM4E (0.71) | FAAHMEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL2927709 | 0.83 | MEN1 (0.73) | FAAHMEN1KMT2AKCNH2SIGMAR1 | |
| SCHEMBL5477755 | 0.83 | FAAH (0.57) | FAAHMEN1KMT2AKCNH2SIGMAR1 | |
| SCHEMBL4719801 | 0.83 | SIGMAR1 (0.66) | MEN1KMT2AKCNH2SIGMAR1 | |
| SCHEMBL2378962 | 0.81 | SIGMAR1 (0.49) | FAAHMEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL22483279 | 0.81 | HTR2A (0.56) | MEN1KMT2AKDM4ESIGMAR1HTR2A | |
| SCHEMBL2307774 | 0.80 | SIGMAR1 (0.60) | FAAHMEN1KMT2AKDM4EKCNH2 | |
| SCHEMBL2377541 | 0.79 | TSHR (0.70) | FAAHKDM4ESIGMAR1POLB | |
| SCHEMBL4717096 | 0.79 | SIGMAR1 (0.71) | FAAHKDM4EKCNH2SIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190111-B1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-9975893-B2 | Pyrazolo[3,4-c]pyridine derivatives | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | disclosed |
| EP-3190111-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | F11, TFPI, F2 | FAAH 4256/4885MEN1 1111/4885KMT2A 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.